PDF(Pubmed)
Abstract：
OBJECTIVE: This study investigated pancreatic enzyme replacement therapy (PERT) use in people diagnosed with pancreatic cancer in New Zealand (NZ) and Australia (AU).
METHODS: A cross-sectional survey study was conducted using a mixed-media campaign to recruit people with pancreatic cancer and collect information about current PERT use. The questionnaire gathered data on participant demographics, awareness of PERT, prescribing practices and efficacy of enzyme replacement.
RESULTS: Over 300 people with pancreatic cancer were recruited, 135 from New Zealand and 199 from Australia. Every region, state and territory was represented except for the West Coast (NZ) and the Northern Territory (AU), the lowest populated areas in both countries. In New Zealand, 60% of participants had heard about PERT, compared to 69.3% in Australia. Dosing regimens were inconsistent in both countries, with 18% and 27% of participants being prescribed PERT considered best practice in New Zealand and Australia, respectively. Before PERT commencement, 70% of participants experienced symptoms of malabsorption, with all symptoms improving after therapy was established. The majority of participants were compliant with their medication.
CONCLUSIONS: PERT use in pancreatic cancer in New Zealand and Australia was highly variable and not compliant with international guidelines in which PERT is recommended as standard therapy. Enzyme replacement is effective for improving the symptoms of malabsorption in patients with pancreatic cancer. Clinician education may be needed to help improve the use of PERT in people with pancreatic cancer.
METHODS: A cross-sectional survey study was conducted using a mixed-media campaign to recruit people with pancreatic cancer and collect information about current PERT use. The questionnaire gathered data on participant demographics, awareness of PERT, prescribing practices and efficacy of enzyme replacement.
RESULTS: Over 300 people with pancreatic cancer were recruited, 135 from New Zealand and 199 from Australia. Every region, state and territory was represented except for the West Coast (NZ) and the Northern Territory (AU), the lowest populated areas in both countries. In New Zealand, 60% of participants had heard about PERT, compared to 69.3% in Australia. Dosing regimens were inconsistent in both countries, with 18% and 27% of participants being prescribed PERT considered best practice in New Zealand and Australia, respectively. Before PERT commencement, 70% of participants experienced symptoms of malabsorption, with all symptoms improving after therapy was established. The majority of participants were compliant with their medication.
CONCLUSIONS: PERT use in pancreatic cancer in New Zealand and Australia was highly variable and not compliant with international guidelines in which PERT is recommended as standard therapy. Enzyme replacement is effective for improving the symptoms of malabsorption in patients with pancreatic cancer. Clinician education may be needed to help improve the use of PERT in people with pancreatic cancer.
摘要：
目的：这项研究调查了在新西兰（NZ）和澳大利亚（AU）诊断为胰腺癌的人群中使用胰酶替代疗法（PERT）的情况。
方法：进行了一项横断面调查研究，使用混合媒体活动招募胰腺癌患者并收集有关当前PERT使用的信息。问卷收集了参与者的人口统计数据，PERT的意识,开处方的做法和酶替代的功效。
结果：招募了300多名胰腺癌患者，135来自新西兰，199来自澳大利亚。每个地区,除西海岸(NZ)和北领地(AU)外，州和领地都有代表，这两个国家人口最低的地区。在新西兰,60%的参与者听说过PERT,相比之下，澳大利亚为69.3%。这两个国家的给药方案不一致，18%和27%的参与者被处方PERT认为是新西兰和澳大利亚的最佳实践，分别。PERT开始前,70%的参与者经历了吸收不良的症状，治疗后所有症状都得到改善。大多数参与者都遵守他们的药物。
结论：在新西兰和澳大利亚的胰腺癌中使用PERT是高度可变的，并且不符合推荐PERT作为标准治疗的国际指南。酶替代可有效改善胰腺癌患者的吸收不良症状。临床医生教育可能需要帮助改善胰腺癌患者PERT的使用。
方法：进行了一项横断面调查研究，使用混合媒体活动招募胰腺癌患者并收集有关当前PERT使用的信息。问卷收集了参与者的人口统计数据，PERT的意识,开处方的做法和酶替代的功效。
结果：招募了300多名胰腺癌患者，135来自新西兰，199来自澳大利亚。每个地区,除西海岸(NZ)和北领地(AU)外，州和领地都有代表，这两个国家人口最低的地区。在新西兰,60%的参与者听说过PERT,相比之下，澳大利亚为69.3%。这两个国家的给药方案不一致，18%和27%的参与者被处方PERT认为是新西兰和澳大利亚的最佳实践，分别。PERT开始前,70%的参与者经历了吸收不良的症状，治疗后所有症状都得到改善。大多数参与者都遵守他们的药物。
结论：在新西兰和澳大利亚的胰腺癌中使用PERT是高度可变的，并且不符合推荐PERT作为标准治疗的国际指南。酶替代可有效改善胰腺癌患者的吸收不良症状。临床医生教育可能需要帮助改善胰腺癌患者PERT的使用。
